News: Innovation and Commercial Partners
A major defence research commercialisation project between the University of Adelaide and the University of New South Wales is one of just eight proposals shortlisted for the Federal Government’s new $242.7 million Trailblazer Universities program.
Fortescue Future Industries, Sparc Technologies and the University of Adelaide partner to tackle the future of clean energy
Sparc Technologies Ltd (ASX: SPN) has entered into binding agreements with global green energy company Fortescue Future Industries Pty Ltd (an entity of Fortescue Metals Group Ltd ASX: FMG) and the University of Adelaide, forming the Sparc Hydrogen Pty Ltd Joint Venture (Sparc Hydrogen).
The University of Adelaide has been awarded more than $8.8 million in research grants from the Federal Government’s Medical Research Future Fund’s (MRFF) to support targeted research on new ways to address risk factors for chronic and complex diseases.
Sparc Technologies Limited (ASX:SPN) is pleased to announce it has received confirmation that the United States (USA) patent application number 15/578149 has now been issued as a patent.
The Australian Lung Health Initiative (ALHI) has been granted $28.9 million in funding from the Australian Federal Government's Medical Research Future Fund (MRFF) Frontier Health and Medical Research initiative, to be provided in tranches over the next five years, to achieve medical breakthroughs with the potential to impact on a global scale.
Industry partner Sparc Technologies Limited (ASX:SPN) recommenced trading on the Australian Securities Exchange (ASX) on Monday 23 November at 10:09am AEDT following the successful completion of its acquisition via reverse takeover, of emerging South Australian graphene technology developer, Graphene Technology Solutions (GTS).
A new design facility, located at the University of Adelaide, will offer organisations and individuals a space in which to push the boundaries of technical, industrial and business innovation.
Researchers at the University of Adelaide have been awarded $1.35 million in funding to accelerate development of a world-first vaccine for the Zika virus.
VivaZome Therapeutics and the University of Adelaide have entered into a series of agreements encompassing licensing of technology, access to stem cells and conduct of research, all in support of VivaZome’s mission to develop and commercialise exosome-based therapeutics.
The University of Adelaide has partnered with medical technology company Sienna Cancer Diagnostics in an exclusive worldwide licence agreement to develop a unique cancer probe with the potential to detect a sugar molecule only present in cancer cells.